SGLT2 Inhibitors vs. GLP-1 Agonists for Type 2 Diabetes: Which Works Better in the Real World?
SGLT2 inhibitors were better at reducing heart failure hospitalizations and had fewer hypoglycemic events, while GLP-1 agonists showed advantages for cardiovascular events and kidney outcomes in real-world data.
Quick Facts
What This Study Found
From 22,100 research articles screened, the systematic review included observational studies comparing SGLT2 inhibitors and GLP-1 receptor agonists in real-world type 2 diabetes patients.
Key pooled analysis findings:
- Heart failure and MACE/revascularization risk ratios were slightly higher with SGLT2 inhibitors compared to GLP-1 agonists (meaning GLP-1 agonists had a slight edge for cardiovascular event reduction)
- Renal outcome odds ratios also slightly favored GLP-1 agonists
- However, SGLT2 inhibitors showed lower hypoglycemic events and lower all-cause mortality rates
- SGLT2 inhibitors were more effective specifically at reducing hospitalization for heart failure
The findings suggest these drug classes have complementary strengths rather than one being universally superior.
Key Numbers
How They Did This
Systematic review following PRISMA guidelines. Researchers searched EMBASE, PubMed, ClinicalTrials.gov, and Cochrane Library for studies published from January 2010 to September 2024. Only observational (real-world) studies were included; randomized controlled trials were excluded to focus on real-world clinical outcomes. Pooled analysis calculated risk ratios and odds ratios for cardiovascular, renal, hypoglycemic, and mortality outcomes.
Why This Research Matters
Both SGLT2 inhibitors and GLP-1 agonists are first-line options for type 2 diabetes with cardiovascular or kidney concerns. Understanding their real-world performance differences helps clinicians choose the right drug for each patient based on their specific risk profile — heart failure risk vs. cardiovascular event risk vs. kidney disease.
The Bigger Picture
This review adds to the growing evidence supporting personalized medicine in diabetes care. Rather than viewing these drug classes as interchangeable, clinicians can now better match patients to the drug class that addresses their primary risk — a shift toward more targeted therapeutic decision-making in a disease affecting hundreds of millions worldwide.
What This Study Doesn't Tell Us
The review included only observational studies, which are subject to selection bias and confounding factors that randomized trials control for. The exclusion of RCTs means the findings may not establish causal relationships. Differences in study populations, drug doses, and follow-up periods across included studies could introduce heterogeneity. The review does not specify how many studies ultimately met inclusion criteria.
Questions This Raises
- ?Would patients with both heart failure risk and cardiovascular event risk benefit from combining SGLT2 inhibitors with GLP-1 agonists?
- ?Do the relative advantages shift with longer treatment durations or in specific patient subgroups?
- ?How do newer dual-mechanism drugs like tirzepatide compare to either class alone?
Trust & Context
- Key Stat:
- 22,100 articles screened Comprehensive systematic review comparing SGLT2 inhibitors and GLP-1 agonists across real-world observational studies spanning 14 years
- Evidence Grade:
- As a systematic review of observational studies, this provides broad real-world evidence synthesis. However, the deliberate exclusion of randomized controlled trials and reliance on observational data means the evidence is subject to confounding biases that limit causal conclusions.
- Study Age:
- Published in 2026 with data through September 2024, this is a very current review reflecting the latest real-world evidence on these widely prescribed drug classes.
- Original Title:
- Treatment outcomes and safety profile of SGLT2 inhibitors versus GLP-1 agonists in type 2 diabetes mellitus : Systematic review of real-world observational studies.
- Published In:
- Wiener medizinische Wochenschrift (1946), 176(1-2), 45-59 (2026)
- Database ID:
- RPEP-14731
Evidence Hierarchy
Frequently Asked Questions
Should I take an SGLT2 inhibitor or a GLP-1 agonist for my type 2 diabetes?
This depends on your individual health profile. This review found SGLT2 inhibitors may be better if heart failure is a primary concern, with lower hypoglycemia rates and mortality. GLP-1 agonists may be preferred if cardiovascular events or kidney disease are the main risks. Your doctor can help determine which fits your situation best.
Why did this review only look at real-world data instead of clinical trials?
The researchers specifically wanted to understand how these drugs perform in everyday clinical practice, where patients are more diverse and conditions less controlled than in clinical trials. Real-world data can reveal patterns in effectiveness and safety that may not appear in the more restrictive settings of randomized controlled trials.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14731APA
Alam, Aftab; Imran, Mohd; Ur Rehman, Zia; Sahoo, Biswa Mohan; Mahapatra, Manoj Kumar. (2026). Treatment outcomes and safety profile of SGLT2 inhibitors versus GLP-1 agonists in type 2 diabetes mellitus : Systematic review of real-world observational studies.. Wiener medizinische Wochenschrift (1946), 176(1-2), 45-59. https://doi.org/10.1007/s10354-025-01108-5
MLA
Alam, Aftab, et al. "Treatment outcomes and safety profile of SGLT2 inhibitors versus GLP-1 agonists in type 2 diabetes mellitus : Systematic review of real-world observational studies.." Wiener medizinische Wochenschrift (1946), 2026. https://doi.org/10.1007/s10354-025-01108-5
RethinkPeptides
RethinkPeptides Research Database. "Treatment outcomes and safety profile of SGLT2 inhibitors ve..." RPEP-14731. Retrieved from https://rethinkpeptides.com/research/alam-2026-treatment-outcomes-and-safety
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.